Books > Science & Mathematics > Biology, life sciences
Not currently available
Loot Price: R770
Discovery Miles 7 700
Share your images
Erik Yama Tienne
Supplier out of stock. If you
add it to your wishlist we will send you an email should it become available again.
Please note that the content of this book primarily consists of
articles available from Wikipedia or other free sources online.
Selumetinib (AZD6244, ARRY-142886), activating mutations in the
BRAF gene, primarily at V600E, are associated with poorer outcomes
in patients with papillary thyroid cancer. MAPK kinase (MEK),
immediately downstream of BRAF, is a promising target for MAPK/ERK
pathway inhibition. In addition to thyroid cancer, BRAF-activating
mutations are prevalent in melanoma (-59%), colorectal cancer
(5-22%), serous ovarian cancer (-30%), and several other tumor
types. Four lines bearing V600E BRAF mutations were all sensitive
to selumetinib, with GI50 clarification needed] values ranging from
14 to 50 nM. A positive control BRAF mutant melanoma line, SKMel28,
exhibited a similar GI50 of 23 nM. A Phase II clinical trial about
selumetinib in cancers with BRAF mutations is ongoing.
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!